An Integrated Microfluidic Chip and Its Clinical Application for Circulating Tumor Cell Isolation and Single‐Cell Analysis

Xu, Mingxin; Zhao, Hui; Chen, Jun; Liu, Wenwen; Li, Encheng; Wang, Qi; Zhang, Lichuan

doi:10.1002/cyto.a.23902

Cited by 26 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six somatic gene mutations were found by single cell analysis on a CTC from a patient with lung cancer. The results were confirmed by tissue biopsy analysis, showing the potential of singe-cell analysis application in CTCs research [ 130 ].…”

Section: Clinical Validation and Trials In Lung Cancermentioning

confidence: 78%

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation

Carvalho

Ferreira

Seixas

et al. 2021

Cancers

View full text Add to dashboard Cite

Despite the intensive efforts dedicated to cancer diagnosis and treatment, lung cancer (LCa) remains the leading cause of cancer-related mortality, worldwide. The poor survival rate among lung cancer patients commonly results from diagnosis at late-stage, limitations in characterizing tumor heterogeneity and the lack of non-invasive tools for detection of residual disease and early recurrence. Henceforth, research on liquid biopsies has been increasingly devoted to overcoming these major limitations and improving management of LCa patients. Liquid biopsy is an emerging field that has evolved significantly in recent years due its minimally invasive nature and potential to assess various disease biomarkers. Several strategies for characterization of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have been developed. With the aim of standardizing diagnostic and follow-up practices, microfluidic devices have been introduced to improve biomarkers isolation efficiency and specificity. Nonetheless, implementation of lab-on-a-chip platforms in clinical practice may face some challenges, considering its recent application to liquid biopsies. In this review, recent advances and strategies for the use of liquid biopsies in LCa management are discussed, focusing on high-throughput microfluidic devices applied for CTCs and ctDNA isolation and detection, current clinical validation studies and potential clinical utility.

show abstract

Section: Clinical Validation and Trials In Lung Cancermentioning

confidence: 78%

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation

Carvalho

Ferreira

Seixas

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…A micromanipulator was used for separating single CTCs as described previously [ 19 ]. Briefly, for manual cell picking, a tapered ultrathin glass capillary (Friends Honesty Life Sciences Company, Beijing, China) was connected with a Teflon tube to aspirate and dispense single cells, under the negative and positive pressures provided by two constant-pressure pumps (WH-PMPP-12, Wenhao Co., Suzhou, China).…”

Section: Methodsmentioning

confidence: 99%

Design and Clinical Application of an Integrated Microfluidic Device for Circulating Tumor Cells Isolation and Single-Cell Analysis

Liu

Zou

et al. 2021

Micromachines

Self Cite

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) have been considered as an alternative to tissue biopsy for providing both germline-specific and tumor-derived genetic variations. Single-cell analysis of CTCs enables in-depth investigation of tumor heterogeneity and individualized clinical assessment. However, common CTC enrichment techniques generally have limitations of low throughput and cell damage. Herein, based on micropore-arrayed filtration membrane and microfluidic chip, we established an integrated CTC isolation platform with high-throughput, high-efficiency, and less cell damage. We observed a capture rate of around 85% and a purity of 60.4% by spiking tumor cells (PC-9) into healthy blood samples. Detection of CTCs from lung cancer patients demonstrated a positive detectable rate of 87.5%. Additionally, single CTCs, ctDNA and liver biopsy tissue of a representative advanced lung cancer patient were collected and sequenced, which revealed comprehensive genetic information of CTCs while reflected the differences in genetic profiles between different biological samples. This work provides a promising tool for CTCs isolation and further analysis at single-cell resolution with potential clinical value.

show abstract

“…Such changes are induced by chemo-and radiotherapy as well as by senescent tumor cells, modifying the tumor microenvironment. One source of CSCs is circulating tumor cells that are not part of this issue but are addressed in recent overviews (13,14).…”

Section: Tumors Meng Et Al Link An Increased Cxcl10 Expression and mentioning

confidence: 99%

Editorial: Modulation of Human Immune Parameters by Anticancer Therapies

et al. 2020

View full text Add to dashboard Cite

Immunoncology is among the most important hallmarks of immunotherapy revolution of cancer medicine. Here, we compiled reviews and original research articles reflecting current developments in immunoncology. Novel therapies modulate the complex interaction between tumor and immune system (Figure 1). Multiparametric flow cytometry (FCM) is a key analytical tool contributing over 1,000 research articles/ year to the field. As a quantitative single-cell technology, FCM reliably and reproducibly identifies rare populations, detects subtle changes in modulatory signals, and assesses time-sensitive antigenic expression patterns. State-of-the-art equipment, fast sophisticated software, and flexibly labeled monoclonal antibodies allow rapid analyses with high sensitivity and specificity, even in routine applications. Lambert et al. explain how new analytes are added to the portfolio of diagnostic and research laboratories. Sample preparation, antibody titration, and appropriate controls are central in cytometric analysis and must be controlled with the necessary rigor and reproducibility (1). Although tumor cell analysis is a key application of cytometry (2, 3), this research topic is dedicated to the modulation of immune parameters, and we only included work focusing on tumorimmune-cell interaction and its disease-course impact. Dendritic cells (DCs) are crucial in tumor protection (4). Lu et al. dissect the interaction of DCs with non-small cell lung cancer (NSCLC) cells, which can induce an immunosuppressive microenvironment and evade immune surveillance. Analysis of costimulatory molecules and pro-/anti-inflammatory cytokines reveals new subpopulations of CD1c+ DCs in coculture with NSCLC. Particularly, the expression of signal molecules and pro-inflammatory cytokines are suppressed, whereas the secretion of anti-inflammatory cytokines by DCs is upregulated, suggesting that NSCLC can induce tolerogenic DCs, blocking DC-mediated anti-tumor immunity. Chemokines and their corresponding receptors play a pivotal role in orchestrating trafficking of immune cells to fulfill their next tasks. CXCL10 has been associated with T cell recruitment into

show abstract

An Integrated Microfluidic Chip and Its Clinical Application for Circulating Tumor Cell Isolation and Single‐Cell Analysis

Cited by 26 publications

References 24 publications

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation

Design and Clinical Application of an Integrated Microfluidic Device for Circulating Tumor Cells Isolation and Single-Cell Analysis

Editorial: Modulation of Human Immune Parameters by Anticancer Therapies

Contact Info

Product

Resources

About